Polaris Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History
Polaris Capital Management, LLC
- $1.77 Billion
- Q4 2024
A detailed history of Polaris Capital Management, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Polaris Capital Management, LLC holds 47,000 shares of SUPN stock, worth $1.8 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
47,000
Previous 42,500
10.59%
Holding current value
$1.8 Million
Previous $1.33 Million
28.23%
% of portfolio
0.1%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
285Shares Held
60.7MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$399 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$235 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$196 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$111 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$101 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.05B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...